McKesson Corporation (NYSE: MCK) is one of the largest healthcare distribution companies in the U.S., supplying pharmaceuticals and medical products to pharmacies, hospitals, and healthcare providers nationwide. Shares recently traded around $809 per share, giving the company a market value of roughly $101.6 billion.
McKesson’s business is built on scale, logistics efficiency, and steady healthcare demand. Looking at who owns the stock and how insiders have been trading helps show how major investors appear to be approaching the company today.
Who Are McKesson’s Top Shareholders?
McKesson’s shareholder base is led by large passive institutions that tend to hold through market cycles, helping keep long-term ownership relatively stable. Active managers adjusted positions in both directions, suggesting a mix of confidence in the business and discipline around valuation. For investors, this ownership structure points to steady institutional support rather than speculative positioning.
- The Vanguard Group: 11,971,748 shares (9.70%), ~$9.86B value. Cut 42,569 shares (0.35%).
- BlackRock Institutional Trust Company: 6,789,774 shares (5.50%), ~$5.59B value. Added 50,944 shares (0.76%).
- State Street Investment Management: 5,750,519 shares (4.66%), ~$4.74B value. Added 51,510 shares (0.90%).
- MFS Investment Management: 3,849,726 shares (3.12%), ~$3.17B value. Cut 69,771 shares (1.78%).
- Geode Capital Management: 2,832,262 shares (2.29%), ~$2.33B value. Added 11,538 shares (0.41%).
- Fidelity Management & Research: 2,739,409 shares (2.22%), ~$2.26B value. Added 832,120 shares (43.63%).
- AllianceBernstein: 2,394,699 shares (1.94%), ~$1.97B value. Added 126,684 shares (5.59%).
- Putnam Investment Management: 2,349,984 shares (1.90%), ~$1.94B value. Added 82,019 shares (3.62%).
Hedge Fund Highlights
One notable move last quarter came from Millennium Management, founded by Israel Englander, which boosted its McKesson position by more than 2,100%. The firm now holds roughly $84 million value in MCK shares, which may indicate increased confidence in McKesson’s earnings durability and defensive healthcare exposure.
Balyasny Asset Management, led by founder Dmitry Balyasny, also raised its McKesson stake by about 155%, bringing its position to approximately $5 million value. The increase suggests the fund may be leaning more positively on McKesson’s scale advantages and predictable cash flow profile.
Another active buyer was Glenview Capital Management, founded by Larry Robbins, which increased its position by roughly 121% to around $44 million value. The move appears consistent with Glenview’s focus on stable, cash-generative healthcare businesses.
Squarepoint Ops, founded by Rami Elkabetz, lifted its McKesson holdings by about 106%, bringing its position to nearly $78 million value. This suggests some systematic and multi-strategy funds may be seeing favorable risk-reward dynamics at current price levels. For investors, hedge fund activity overall looks mixed but constructive rather than crowded.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
McKesson’s Recent Insider Trades
Insider filings show mostly small transactions spread across executives and directors, with activity leaning toward modest selling alongside equity-related acquisitions.
- Brian Scott Tyler (Officer, Director): Sold 11,930 shares on 8/14/25 at ~$678 and on 8/21/25 at ~$706.
- Napoleon B. Rutledge Jr. (Officer): Sold 329 shares on 8/7/25 at ~$664 and 329 shares on 11/6/25 at ~$862.
- Multiple directors: Acquired ~301 shares each on 7/29/25 at $0.
- Other directors: Acquired between 168 and 301 shares each, representing 0.00% of shares outstanding.
These transactions are small relative to McKesson’s total share count and do not materially affect insider ownership levels. For investors, insider activity appears incremental and administrative rather than signaling a strong directional view on the stock.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
McKesson’s ownership remains anchored by large institutions like Vanguard, BlackRock, and State Street, providing long-term stability. Active managers and hedge funds appear selective, with some increasing exposure while others trim, which may reflect valuation sensitivity after recent gains.
Insider activity remains modest and dispersed, offering context rather than a clear signal. For investors, the data suggest McKesson continues to be viewed as a high-quality, defensively positioned healthcare distributor with steady institutional confidence.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
